
Pelacarsen (Lp(a)HORIZON) and ziltivekimab (ZEUS) cut their targets but not heart events
Shared summary of two NEJM trials. Pelacarsen lowered Lp(a) sharply but event rates were 12.3% vs 12.1% on placebo, and ziltivekimab cut CRP and IL-6 but events were 17.6% vs 17.7%. The post notes prior biomarker failures (torcetrapib, dalcetrapib), and that both trials enrolled people with existing disease and so do not prove Lp(a) or inflammation are not causal.

